CA Patent

CA2652553A1 — Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease

Assigned to Amicus Therapeutics Inc · Expires 2007-11-29 · 18y expired

What this patent protects

Provided are uses of 1-deoxygalactonojirimycin or a salt for treating Fabry disease and/or for enhancing .alpha.-galactosidase A activity.

USPTO Abstract

Provided are uses of 1-deoxygalactonojirimycin or a salt for treating Fabry disease and/or for enhancing .alpha.-galactosidase A activity.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

Patent Metadata

Patent number: CA2652553A1
Jurisdiction: CA
Classification: —
Expires: 2007-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.